CompletedAge-related condition
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series
- Sponsor
- Cytrellis Biosystems, Inc. (Industry)
- Enrolment
- 9 enrolled
- Conditions
- glp1 Agonist; Gene Expression; Skin Laxity
- Interventions
- ellacor
- Ages
- adults, older adults
- Registry
- NCT07224880
Full record on ClinicalTrials.gov
From the registry
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity
Primary outcomes
- Safety and Outcomes
History
Last registry update
Primary completion
Registered
Started